Literature DB >> 22095438

Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation.

Livia Bernardin1, Philip Dilks, Sidath Liyanage, Marc E Miquel, Anju Sahdev, Andrea Rockall.   

Abstract

OBJECTIVES: To determine whether threshold criteria using semi-quantitative multiphase-dynamic contrast-enhanced magnetic resonance imaging (DCE- MRI) can improve prediction of malignancy in complex adnexal masses.
METHODS: MRI features of 70 complex adnexal masses with enhancing components in 63 patients were reviewed and correlated with histopathology (n = 67) or radiological follow-up (n = 3). Masses were categorised as benign (n = 34) or borderline/invasive malignant (n = 36). Borderline lesions (n = 6) were also analysed separately. Using the semi-quantitative breast analysis software, regions of interest were drawn around the most avidly enhancing component of each lesion. Maximum absolute enhancement of signal intensities (SI(max)), maximum relative enhancement (SI(rel)) and wash-in rate (WIR) were recorded. Optimal threshold criteria were established to predict borderline/invasive malignancy.
RESULTS: There was a significant difference in mean SI(max) (P < 0.05), SI(rel) (P < 0.01) and WIR (P < 0.001) between benign and borderline/invasive malignant groups. A cut-off WIR ≥ 9.5 l/s had a specificity of 88% and positive predictive value of 86% for predicting malignancy, significantly better than conventional MRI (62%, P < 0.01). WIR <8.2 l/s had a negative predictive value of 94%.
CONCLUSION: Threshold criteria using semi-quantitative multiphase DCE-MRI improves specificity in the prediction of malignancy in complex adnexal masses with enhancing components and is complementary to standard qualitative assessment. KEY POINTS: Semi-quantitative DCE-MRI threshold criteria are effective for predicting ovarian malignancy. The surgical approach may be altered depending on DCE-MRI threshold criteria analysis. Borderline tumours demonstrate significant overlap with benign lesions using DCE-MRI threshold criteria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095438     DOI: 10.1007/s00330-011-2331-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  24 in total

1.  Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging.

Authors:  Isabelle Thomassin-Naggara; Irwin Toussaint; Nicolas Perrot; Roman Rouzier; Charles A Cuenod; Marc Bazot; Emile Daraï
Journal:  Radiology       Date:  2010-12-30       Impact factor: 11.105

2.  MRI of sonographically indeterminate adnexal masses.

Authors:  Saroja Adusumilli; Hero K Hussain; Elaine M Caoili; William J Weadock; John P Murray; Timothy D Johnson; Qixuan Chen; Benoit Desjardins
Journal:  AJR Am J Roentgenol       Date:  2006-09       Impact factor: 3.959

3.  Diffusion-weighted imaging of solid or predominantly solid gynaecological adnexial masses: is it useful in the differential diagnosis?

Authors:  B Bakir; S Bakan; M Tunaci; V L Bakir; A C Iyibozkurt; S Berkman; E Bengisu; A Salmaslioglu
Journal:  Br J Radiol       Date:  2010-11-16       Impact factor: 3.039

4.  Diffusion-weighted echo-planar MR imaging and ADC mapping in the differential diagnosis of ovarian cystic masses: usefulness of detecting keratinoid substances in mature cystic teratomas.

Authors:  Tomohiro Nakayama; Kengo Yoshimitsu; Hiroyuki Irie; Hitoshi Aibe; Tsuyoshi Tajima; Akihiro Nishie; Yoshiki Asayama; Kunishige Matake; Daisuke Kakihara; Shuji Matsuura; Hitoo Nakano; Hiroshi Honda
Journal:  J Magn Reson Imaging       Date:  2005-08       Impact factor: 4.813

5.  Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy.

Authors:  P O van Trappen; B D Rufford; T D Mills; S A Sohaib; J A W Webb; A Sahdev; M J Carroll; K E Britton; R H Reznek; I J Jacobs
Journal:  Int J Gynecol Cancer       Date:  2007 Jan-Feb       Impact factor: 3.437

Review 6.  Ovarian Cancer Management: the role of imaging and diagnostic challenges.

Authors:  Nishat Bharwani; Rodney H Reznek; Andrea G Rockall
Journal:  Eur J Radiol       Date:  2011-03-09       Impact factor: 3.528

7.  The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index.

Authors:  A P Davies; I Jacobs; R Woolas; A Fish; D Oram
Journal:  Br J Obstet Gynaecol       Date:  1993-10

8.  Risk of malignancy index in the preoperative evaluation of pelvic masses.

Authors:  B R Obeidat; Z O Amarin; J A Latimer; R A Crawford
Journal:  Int J Gynaecol Obstet       Date:  2004-06       Impact factor: 3.561

9.  Magnetic resonance diffusion imaging of ovarian masses: a first experience with 12 cases.

Authors:  Gordon E Sarty; Edward J Kendall; John Loewy; Anita Dhir; Olufemi A Olatunbosun; Roger A Pierson
Journal:  MAGMA       Date:  2004-02-27       Impact factor: 2.310

10.  MRI appearances of borderline ovarian tumours.

Authors:  C L Bent; A Sahdev; A G Rockall; N Singh; S A Sohaib; R H Reznek
Journal:  Clin Radiol       Date:  2008-12-20       Impact factor: 2.350

View more
  21 in total

1.  The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions.

Authors:  Xian Li; Jun-Li Hu; Lai-Min Zhu; Xin-Hai Sun; Hua-Qiang Sheng; Ning Zhai; Xi-Bin Hu; Chu-Ran Sun; Bin Zhao
Journal:  Tumour Biol       Date:  2015-02-28

2.  The MRI features of histologically proven ovarian cystadenofibromas-an assessment of the morphological and enhancement patterns.

Authors:  Yen Zhi Tang; Sid Liyanage; Priya Narayanan; Anju Sahdev; Aslam Sohaib; Naveena Singh; Andrea Rockall
Journal:  Eur Radiol       Date:  2012-07-20       Impact factor: 5.315

3.  Use of an internal reference in semi-quantitative dynamic contrast-enhanced MRI (DCE MRI) of indeterminate adnexal masses.

Authors:  Y Z Tang; L Benardin; T C Booth; M E Miquel; P Dilks; A Sahdev; A G Rockall
Journal:  Br J Radiol       Date:  2014-09-19       Impact factor: 3.039

Review 4.  Multimodality imaging review of complex pelvic lesions in female pelvis.

Authors:  Anuradha Chandramohan; Tameem Ahmed Bhat; Reetu John; Betty Simon
Journal:  Br J Radiol       Date:  2020-09-04       Impact factor: 3.039

5.  Semi-quantitative contrast-enhanced MR analysis of indeterminate ovarian tumours: when to say malignancy?

Authors:  S M Mansour; S Saraya; Y El-Faissal
Journal:  Br J Radiol       Date:  2015-06-17       Impact factor: 3.039

Review 6.  What's New in Imaging for Gynecologic Cancer?

Authors:  Sairah R Khan; Mubarik Arshad; Kathryn Wallitt; Victoria Stewart; Nishat Bharwani; Tara D Barwick
Journal:  Curr Oncol Rep       Date:  2017-11-06       Impact factor: 5.075

Review 7.  O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.

Authors:  Elizabeth A Sadowski; Isabelle Thomassin-Naggara; Andrea Rockall; Katherine E Maturen; Rosemarie Forstner; Priyanka Jha; Stephanie Nougaret; Evan S Siegelman; Caroline Reinhold
Journal:  Radiology       Date:  2022-01-18       Impact factor: 11.105

Review 8.  Ovary: MRI characterisation and O-RADS MRI.

Authors:  Elizabeth A Sadowski; Katherine E Maturen; Andrea Rockall; Caroline Reinhold; Helen Addley; Priyanka Jha; Nishat Bharwani; Isabelle Thomassin-Naggara
Journal:  Br J Radiol       Date:  2021-04-30       Impact factor: 3.629

9.  Multicentre external validation of IOTA prediction models and RMI by operators with varied training.

Authors:  A Sayasneh; L Wynants; J Preisler; J Kaijser; S Johnson; C Stalder; R Husicka; Y Abdallah; F Raslan; A Drought; A A Smith; S Ghaem-Maghami; E Epstein; B Van Calster; D Timmerman; T Bourne
Journal:  Br J Cancer       Date:  2013-05-14       Impact factor: 7.640

10.  Enhancement of ovarian malignancy on clinical contrast enhanced MRI studies.

Authors:  Harpreet K Pannu; Weining Ma; Emily Craig Zabor; Chaya S Moskowitz; Richard R Barakat; Hedvig Hricak
Journal:  ISRN Obstet Gynecol       Date:  2013-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.